Covaxin can protect against COVID-19 mutant: Bharat Biotech
Bharat Biotech MD also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with ICMR and the National Institute of Virology and now undergoing phase 3 trials
PTI | December 29, 2020 | Updated 20:55 IST
The executive said Covaxin, now undergoing Phase 3 trials involving about 20,000 volunteers, balances both safety and efficacy
Covaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of coronavirus, Chairman and Managing Directorof the city-based vaccine maker Krishna Ella said on Tuesday. He also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology and now undergoing phase 3 trials.